US Bayer lawsuit: Teva admits to false generic Yaz label information
This article was originally published in Scrip
Executive Summary
The US unit of Teva Pharmaceutical Industries has admitted in a court proceeding that the physician prescribing information for its recently launched generic version of Yaz (drospirenone plus ethinylestradiol) falsely claims that the product uses Bayer's patented stabiliser formulation, and has agreed to correct the labelling.